

ARTISAN® Hyperopia PIOL | US Phase III Clinical Investigation

In April 2000, the U.S. Clinical Investigation of the Artisan® Hyperopia Lens began. Since then, a total of nine investigation sites have participated Phase III of the study, nearly completing the protocol enrollment. All study subjects will be monitored for a minimum of two years to determine the safety and efficacy of the device.

Study Inclusion Criteria

- Correction of axial hyperopia from +3.0 D to +12.0 D
- Preoperative endothelial cell count ≥ 2000 c/mm² diameter
- Subject age ranges from 20 to 50 years.
- Anterior chamber depth ≥ 3.2 mm
- Mesopic pupil size \leq IOL Optic
- Preoperative cylinder ≤ 2.5 D.

PREOP

Preoperative Observations			Operative Information			IOL Power Distribution		
N=30								
Parameter	Mean	Range	Anesthesia	%	Surgical App.	%		
Pupil diameter (mm)	4.3	3.0 - 5.0	- Peribulbar	53.1	- Superior	62.5		
ACD (mm)	3.3	3.2 - 3.6	- Retrobulbar	43.7	- Temporal	37.5		
Axial length (mm)	21.77	19.4 - 22.8	- Topical	3.1				
Corneal curvature (K1+K2)/2 (D)	42.63	40.8 - 47.3	Incision Loc.	%	Incision size	%		
Intraocular pressure (mmHg)	11.8	10 - 19	- Corneal	31.2	- 5.0	9.4		
Endothelial cell count (c/mm ²)	2276	2000 - 3607	- Limbal	28.1	- 5.2	59.4		
			- Scleral	40.6	- 5.5	18.7		
					- 5.7 - 6.0	12.5		

POSTOP

Accuracy / Predictability Manifest Refraction (6 months)	Stability Spherical Equivalents	Post-Op UCVA (6 months)												
<p>Individuals Achieved Manifest Sph. Equiv. @6 Months (N=28)</p> <p>35% Achieved Correctly with +/- 0.5 D of Intended 98% Achieved Correctly with +/- 1.0 D of Intended</p> <p>Undercorrected Overcorrected</p>	<p>Spherical Equivalent</p> <p>Pre-op: -5.36 D Goal: -0.49 D at Mo. 6: -0.67 D</p> <p>N=60 n=29 n=22 n=23 n=17 n=8</p>	<p>83% 20/40 or Better PostOp</p> <p>Number of Eyes</p> <p>Efficacy</p>												
<p>Lines of BSCVA Gained / Lost (6 months)</p> <p>22% Gained ≥ 1 Line 4% Gained ≥ 2 Lines n=23</p> <p>17% Lost 1 Line</p>	<table border="1"> <thead> <tr> <th></th> <th>Pre-op</th> <th>6 Mo.</th> </tr> </thead> <tbody> <tr> <td>Mean</td> <td>2332</td> <td>2467</td> </tr> <tr> <td>Std. dev.</td> <td>284</td> <td>381</td> </tr> <tr> <td>Cumulative %</td> <td></td> <td>+5.8%</td> </tr> </tbody> </table> <p>N = 23 (same patient data)</p>		Pre-op	6 Mo.	Mean	2332	2467	Std. dev.	284	381	Cumulative %		+5.8%	<p>Preop BSCVA vs Postop BSCVA</p> <p>n = 23</p> <p>Safety</p>
	Pre-op	6 Mo.												
Mean	2332	2467												
Std. dev.	284	381												
Cumulative %		+5.8%												

Complications

2 subjects were observed to have pigment on the natural lens postoperatively. These subjects developed posterior synechiae inferiorly and were treated. Both cases resolved without sequelae. The prognosis is excellent. The cause was determined to be excessive iris touch. The patient selection criteria has been modified to exclude subjects with abnormal or protruding bulging irises.